Biosimilar Insulin Aspart

About Wockhardt

Wockhardt's mission is to address unmet medical needs through research, with a strategic pivot towards combating the global crisis of antimicrobial resistance (AMR). Its key achievement is the development of a late-stage pipeline of novel antibiotic combinations, most notably Zaynich (WCK 5222), which has filed for marketing authorization in India, the US, and EU after a successful global Phase III trial. The company's strategy leverages its deep expertise in complex chemistry and anti-infective R&D to develop first-in-class therapies, while maintaining a foundation of diversified pharmaceutical businesses and hospital services to support its innovative endeavors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals' mission is to develop, manufacture, and market essential, high-barrier-to-entry pharmaceuticals, with a strategic focus on complex generics, proprietary products, and biosimilars. The company has achieved significant recognition, including an FDA Drug Shortage Assistance Award for its subsidiary, and commercial success with market-leading products like BAQSIMI® nasal glucagon. Its strategy leverages a fully integrated operational model, combining proprietary technology platforms in drug delivery with a diversified portfolio targeting endocrinology, pulmonology, and nephrology to drive sustainable growth.

Therapeutic Areas

Other Diabetes Mellitus Drugs